Hospital

Study results show at a molecular level how fidaxomicin selectively targets these bacteria, while sparing others in the gut microbiome.

Getting an appointment with an infectious diseases specialist, particularly after giving birth and while managing a chronic disorder, such as substance use, is difficult, investigators say.

Strong support from pharmacy professionals and a shift in systems and workflows help pave the way for success.

Cutaneous squamous cell carcinoma should be diagnosed early and treated promptly to avoid complications.

A multidisciplinary team of nurse practitioners and pharmacists can work together to address patients at an increased risk for hospital readmission.

In studies of rats, results show that supplementation preserves skeletal muscle after patients take the chemotherapy medication doxorubicin.

A variety of strategies can help increase patient adherence to oral chemotherapy.

Peptide-targeted radionuclide therapy FAP-2286 (Clovis Oncology) showed potent affinity for human fibroblast activation protein by biochemical and cell-based assays.

In an interview with Pharmacy Times®, Ryan Haumschild, PharmD, MS, MBA director of pharmacy at Emory Healthcare and Winship Cancer Institute, discusses the pharmacists role in care teams for targeted therapies at the Academy of Managed Care Pharmacy Annual Meeting.

In a clinical trial, 86.4% of patients on semaglutide achieved a 5% weight loss at week 68 compared to 31.5% with placebo.

Technology clears the way to offer clinical-focused tasks, ultimately improving job satisfaction and minimizing burnout.

Poster at AACR highlights in vitro and in vivosynthetic lethality activity of rucaparib in multiple cancer cell types and PDX tumors that harbor genetic or epigenetic alterations in non-BRCA HRR genes.

Genome sequencing shows the clonality of outbreak isolates within each of 6 classes, which confirmed that recent transmissions accounted for high carriage.

Betrixaban (Bevyxxa) is a factor Xa inhibitor indicated for the prophylaxis of venous thromboembolism in adult patients.

On average, patients visit their community pharmacist 12 times more often than they do their primary care provider

Obesity and a limited physical activity are key factors in post-COVID-19 recovery.

Phase 3 REST-ON Trial data show that the medication demonstrated clinically meaningful improvement in assessments of disrupted nighttime sleep compared with the placebo.

Those hospitalized for COVID-19 were 21% more likely to develop shingles.

Study finds that health care providers need to reinforce the importance of annual mammograms among patients who survived breast cancer.

In an interview with Pharmacy Times®, Chelsee Jensen, PharmD, pharmaceutical formulary manager at Mayo Clinic, discusses biosimilar usage in health systems and challenges that come with it.

Sarah Wheeler, PharmD, BCOP, clinical pharmacy specialist in Hematology/Oncology at UF Health Shands Cancer Hospital, discusses some of the barriers patients with cancer may experience that oncology pharmacists can help them navigate through.

If all HHC agencies adopted policies requiring staff influenza vaccinations, the researchers predicted an 11.25% reduction in the rate of hospital transfers due to respiratory infections.

Medication reconciliation and pharmacist counseling are crucial to clinical management of patients with hematologic malignancies.

Recent studies that indicated the efficacy of IVIG in patients with myelin oligodendrocyte glycoprotein antibody-associated disease used pediatric cohorts, with few evaluations of the treatment approach in adults.

Study captures the immune effect of the third dose of the COVID-19 vaccine in patients with plasma cell disorders and blood cancers.

Pharmacists who educate patients with multiple sclerosis and expand their understanding and knowledge of the condition empowers them to take part in a more active role in managing their health.

Melissa Johnson, MD, program director of Lung Cancer Research at the Sarah Cannon Research Institute, discusses her presentation at the Community Oncology Alliance 2022 conference on new drugs in the non-small cell lung cancer space.

Jim Schwartz, RPh, executive director of pharmacy operations for Oncology Pharmacy Services, discusses his presentation at the Community Oncology Alliance 2022 conference on the new world of oral cancer drug dispensing.

In an interview with Pharmacy Times®, Eric Tichy, PharmD, MBA, BCPS, FAST, FCCP, Vice Chair of Pharmacy/Formulary at Mayo Clinic, discusses some formulary trends in biosimilars at the Academy of Managed Care Pharmacy Annual Meeting.

Additional support is necessary to ensure that infrastructure development continues and that all pharmacists have the necessary tools to continue to provide immunization services.